MedPath

Adanate, Inc.

Adanate, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2018-01-01
Employees
1
Market Cap
-
Website
http://adanate.com

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

Phase 1
Terminated
Conditions
Solid Tumor, Adult
Interventions
Drug: PD(L)-1 inhibitor
First Posted Date
2022-11-01
Last Posted Date
2025-01-28
Lead Sponsor
Adanate, Inc
Target Recruit Count
46
Registration Number
NCT05601219
Locations
🇺🇸

HonorHealth, Scottsdale, Arizona, United States

🇺🇸

Florida Cancer Specialists, Orlando, Florida, United States

🇺🇸

Duke University, Durham, North Carolina, United States

and more 2 locations

News

No news found
© Copyright 2025. All Rights Reserved by MedPath